229 related articles for article (PubMed ID: 27911106)
1. Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4.
Terao E; Nakakura S; Fujisawa Y; Fujio Y; Matsuya K; Kobayashi Y; Tabuchi H; Yoneda T; Fukushima A; Kiuchi Y
Curr Eye Res; 2017 May; 42(5):738-742. PubMed ID: 27911106
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% Ripasudil ophthalmic solution clinical trial.
Sakamoto E; Ishida W; Sumi T; Kishimoto T; Tada K; Fukuda K; Yoneda T; Kuroiwa H; Terao E; Fujisawa Y; Nakakura S; Jian K; Okumichi H; Kiuchi Y; Fukushima A
Sci Rep; 2019 Mar; 9(1):3755. PubMed ID: 30842572
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Long-Term Ripasudil 0.4% Instillation for the Reduction of Intraocular Pressure in Japanese Open-Angle Glaucoma Patients.
Maruyama Y; Ikeda Y; Mori K; Yoshii K; Ueno M; Sotozono C; Kinoshita S
J Ocul Pharmacol Ther; 2020 May; 36(4):229-233. PubMed ID: 32175792
[No Abstract] [Full Text] [Related]
4. Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4.
Terao E; Nakakura S; Fujisawa Y; Nagata Y; Ueda K; Kobayashi Y; Oogi S; Dote S; Shiraishi M; Tabuchi H; Yoneda T; Fukushima A; Asaoka R; Kiuchi Y
BMJ Open Ophthalmol; 2020; 5(1):e000538. PubMed ID: 32818152
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma.
Kusuhara S; Katsuyama A; Matsumiya W; Nakamura M
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):809-814. PubMed ID: 29468405
[TBL] [Abstract][Full Text] [Related]
6. Changes in corneal endothelial cell shape after treatment with one drop of ROCK inhibitor.
Matsumura R; Inoue K; Shiokawa M; Ono M; Tanihara H; Ishida K; Tomita G
Int Ophthalmol; 2020 Feb; 40(2):411-417. PubMed ID: 31664638
[TBL] [Abstract][Full Text] [Related]
7. Association between glaucoma eye drops and hyperemia.
Yanagi M; Kiuchi Y; Yuasa Y; Yoneda T; Sumi T; Hoshikawa Y; Kobayashi M; Fukushima A
Jpn J Ophthalmol; 2016 Mar; 60(2):72-7. PubMed ID: 26847553
[TBL] [Abstract][Full Text] [Related]
8. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma.
Komizo T; Ono T; Yagi A; Miyata K; Aihara M
Jpn J Ophthalmol; 2019 Jan; 63(1):40-45. PubMed ID: 30368633
[TBL] [Abstract][Full Text] [Related]
9. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy.
Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2009-2015. PubMed ID: 28711991
[TBL] [Abstract][Full Text] [Related]
10. A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia.
Hsu CR; Chen YH; Liu CP; Chen CH; Huang KK; Huang JW; Lin MN; Lin CL; Chen WR; Hsu YL; Lee TC; Chou SH; Tu CM; Hwang CS; Huang YC; Lu DW
Invest Ophthalmol Vis Sci; 2019 Feb; 60(2):624-633. PubMed ID: 30735565
[TBL] [Abstract][Full Text] [Related]
11. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
Acta Ophthalmol; 2015 Jun; 93(4):e254-60. PubMed ID: 25487877
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Patterns and Correlations of the Degree of Conjunctival Hyperemia Induced by Omidenepag Isopropyl 0.002% and Ripasudil 0.4.
Terao E; Nakakura S; Nagata Y; Dote S; Tabuchi H; Kiuchi Y
Cureus; 2020 Sep; 12(9):e10368. PubMed ID: 33062491
[TBL] [Abstract][Full Text] [Related]
13. Effects of ripasudil hydrochloride hydrate (K-115), a Rho-kinase inhibitor, on ocular blood flow and ciliary artery smooth muscle contraction in rabbits.
Ohta Y; Takaseki S; Yoshitomi T
Jpn J Ophthalmol; 2017 Sep; 61(5):423-432. PubMed ID: 28653193
[TBL] [Abstract][Full Text] [Related]
14. Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicentre historical cohort study.
Futakuchi A; Morimoto T; Ikeda Y; Tanihara H; Inoue T;
Sci Rep; 2020 Jun; 10(1):10308. PubMed ID: 32587304
[TBL] [Abstract][Full Text] [Related]
15. Effects of Ripasudil Hydrochloride Hydrate Instillation on Pupil Dynamics.
Satou T; Ishikawa H; Asakawa K; Goseki T; Shimizu K
Curr Eye Res; 2017 Jan; 42(1):54-57. PubMed ID: 27249066
[TBL] [Abstract][Full Text] [Related]
16. Safety, efficacy, and patient selection of ripasudil in patients with uncontrolled glaucoma with maximum conventional medical therapy.
Jethva J; Bhagat P; Prajapati K; Tank G
Indian J Ophthalmol; 2022 Jun; 70(6):2020-2023. PubMed ID: 35647972
[TBL] [Abstract][Full Text] [Related]
17. Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine.
Tanihara H; Yamamoto T; Aihara M; Koizumi N; Minami H; Kojima S; Isobe T; Kanazawa M; Suganami H;
Adv Ther; 2023 Aug; 40(8):3559-3573. PubMed ID: 37330927
[TBL] [Abstract][Full Text] [Related]
18. Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy.
Sato S; Hirooka K; Nitta E; Ukegawa K; Tsujikawa A
Adv Ther; 2016 Sep; 33(9):1628-34. PubMed ID: 27438467
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study.
Tanihara H; Kakuda T; Sano T; Kanno T; Gunji R
BMC Ophthalmol; 2020 Jul; 20(1):275. PubMed ID: 32646383
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the Additional Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients With Glaucoma Inadequately Controlled Under Maximum Medical Therapy.
Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
J Glaucoma; 2017 Feb; 26(2):96-100. PubMed ID: 27661993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
